Compare USFD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USFD | MRNA |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 21.5B |
| IPO Year | 2016 | 2018 |
| Metric | USFD | MRNA |
|---|---|---|
| Price | $93.34 | $44.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | ★ $103.64 | $34.27 |
| AVG Volume (30 Days) | 1.7M | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.54 | 21.77 |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $39,424,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $7.63 | $9.36 |
| Revenue Next Year | $3.92 | $15.43 |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | 4.08 | ★ 4.29 |
| 52 Week Low | $66.62 | $22.28 |
| 52 Week High | $102.13 | $59.55 |
| Indicator | USFD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 34.62 |
| Support Level | $87.89 | $23.52 |
| Resistance Level | $94.29 | $55.36 |
| Average True Range (ATR) | 2.20 | 2.87 |
| MACD | 0.10 | -1.00 |
| Stochastic Oscillator | 68.34 | 13.14 |
US Foods Holding Corp is a U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, education, government facilities, and grocers. It has various customer locations across the United States, with a vast network of distribution facilities, a fleet of trucks, and cash and carry locations offering food and non-food products, and a comprehensive suite of e-commerce, technology, and business solutions to its customers. The company operates in one business segment in which it markets, sells, and distributes fresh, frozen, and dry food and non-food products to foodservice customers throughout the U.S. The products offered are as snacks, beverages, fresh produce, sauces, condiments, canned/frozen fruits and others.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.